Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
RXRXRecursion Pharmaceuticals, Inc.
| Figure | RXRXRecursion Pharmaceuticals, Inc.FY2025 · Dec |
|---|---|
| Revenue | $74.68M |
| Revenue, yoy | +26.9% |
| Net income | $644.76M |
| Net income, yoy | −39.1% |
| Net margin | -863.4% |
| Free cash flow | $378.28M |
| FCF margin | -506.5% |
| EPS, diluted | $1.44 |
Add another company.
Annual · FY2021–FY2025 · USD
From SEC EDGARSame fiscal periods, as filed